The classical complement pathway is one of three major routes that activate the complement system, a network of circulating and cell-associated proteins involved in immune defense and tissue clearance. It is commonly initiated when the C1 complex recognizes antibodies bound to a target, although certain non-antibody ligands can also initiate activation. A sequence of protein-cleavage reactions generates enzymes that activate complement component C3 and subsequently C5, promoting target recognition by immune cells, inflammation, and, on susceptible membranes, formation of membrane-damaging pores. The pathway connects adaptive immunity with the effector mechanisms of innate immunity.
Recognition and initiation
The initiating C1 complex consists of the recognition molecule C1q and two molecules each of the proteases C1r and C1s, conventionally written as . Calcium ions help maintain the assembled complex.
C1q has six globular recognition heads attached to collagen-like stalks. In antibody-dependent activation, its heads recognize appropriately arranged Fc regions—the constant portions of antibodies—after the antibodies have bound an antigen. Binding to multiple nearby Fc regions favors activation of C1r, which then activates C1s.
The principal complement-activating antibody classes in humans are IgM and certain subclasses of immunoglobulin G:
- IgM is especially efficient because its multimeric structure can present several C1q-binding sites after attachment to a target.
- IgG3 and IgG1 generally activate the classical pathway efficiently.
- IgG2 can activate it under suitable conditions, particularly where antigen organization supports sufficient antibody clustering.
- IgG4 generally does not activate the classical pathway.
Antibody binding alone is therefore not sufficient to guarantee strong complement activation. Antibody subclass, antigen density, and the spacing and organization of bound antibodies influence whether C1q engages productively. Neighboring IgG molecules can form ordered Fc assemblies that favor C1 recognition.
The pathway is not exclusively antibody-dependent. C1q can recognize structures exposed on cells undergoing apoptosis, as well as certain microbial components. It can also engage target-bound recognition proteins such as C-reactive protein. These interactions contribute to the removal of damaged cells and cellular debris.
The proteolytic cascade
The central reactions involve sequential activation of complement components C4, C2, C3, and C5. Most early components circulate in inactive forms; activation produces fragments with distinct enzymatic, binding, or signaling functions.
Formation of the C3 convertase
Activated C1s cleaves C4 into C4a and C4b. Cleavage exposes a reactive thioester in C4b, enabling it to attach covalently to nearby molecules on a target surface. C4b that does not attach rapidly loses this attachment capacity through reaction with water.
Surface-bound C4b recruits C2, which C1s then cleaves. In the conventional nomenclature used here, the larger enzymatic fragment, C2a, remains associated with C4b to form C4b2a, the classical-pathway C3 convertase.
C2 fragment terminology is an exception to the usual complement convention in which “a” denotes the smaller fragment and “b” the larger fragment. Some revised nomenclature calls the larger C2 fragment C2b and the convertase C4b2b; C4b2a remains widely used.
C3 activation and amplification
C4b2a acts as an enzyme that cleaves many C3 molecules into C3a and C3b. C3a is a soluble inflammatory mediator. C3b exposes a reactive thioester and can attach covalently to nearby surfaces.
Deposited C3b has two major roles:
- It labels the target for recognition by complement receptors.
- It supports further complement activation.
The alternative complement pathway can amplify C3b deposition after classical-pathway initiation. Thus, the amount of complement deposited on a target may reflect both the initiating classical pathway and subsequent alternative-pathway amplification.
C5 activation and the terminal pathway
Association of additional C3b with the C3 convertase generates a C5-cleaving complex, conventionally represented as C4b2a3b. This C5 convertase splits C5 into C5a and C5b.
C5a is a potent inflammatory and cell-recruiting mediator. C5b initiates sequential association with C6, C7, C8, and multiple C9 molecules to form the membrane attack complex, also called C5b–9. This complex can form pores in susceptible cell membranes.
The terminal pathway is shared by all three major complement activation routes; it is not unique to classical activation.
Biological functions
Opsonization and phagocytosis
C3b and its breakdown product iC3b act as opsonins: surface labels that make targets easier for immune cells to recognize and engulf. Complement receptors on neutrophils, macrophages, and other cells bind these fragments, supporting phagocytosis of microbes and cellular debris.
For many targets, opsonization is a more important consequence of complement activation than direct membrane damage.
Inflammatory signaling
C3a and C5a, often called anaphylatoxins, act through specific cell-surface receptors. Their effects include changes in vascular permeability and activation or recruitment of immune cells. C5a is particularly important in attracting and activating neutrophils.
These responses help localize immune activity but can also contribute to tissue injury when activation is excessive or poorly controlled.
Clearance of immune complexes and dying cells
Complement coating helps remove antigen–antibody complexes from circulation. In humans, complement receptor 1 on erythrocytes binds complement-coated complexes and helps transport them to clearance sites, particularly in the liver and spleen.
Recognition of dying cells also supports disposal of cellular material before it accumulates or provokes inappropriate immune responses.
Direct membrane injury
The membrane attack complex is particularly important in defense against certain bacteria, notably Neisseria. Its effectiveness varies with target membrane structure and complement resistance mechanisms. It does not efficiently lyse all microorganisms, and nucleated host cells possess protective mechanisms that limit terminal-complex injury.
Regulation
Classical-pathway activity is restricted by soluble and membrane-associated regulators.
- C1 inhibitor inhibits activated C1r and C1s, limiting initiation.
- C4-binding protein promotes decay of the C3 convertase and acts as a cofactor for factor I-mediated inactivation of C4b.
- Factor I, with appropriate cofactors, cleaves C4b and C3b into forms that no longer support the same convertase functions.
- CD55, also called decay-accelerating factor, accelerates convertase dissociation.
- CD46 and complement receptor 1 provide cofactor activity for factor I.
- CD59 inhibits terminal-complex formation by interfering with C9 incorporation.
The short lifetime of active convertases and the rapid loss of attachment capacity by unbound C4b and C3b further constrain activation. Together, these mechanisms help concentrate complement activity near initiating targets and protect host tissues.
Relationship to other complement pathways
The three major pathways differ primarily in recognition and early convertase assembly:
| Pathway | Typical initiation | C3 convertase |
|---|---|---|
| Classical | C1 recognition of target-bound antibodies or other ligands | C4b2a |
| [[lectin-complement-pathway | Lectin]] | Recognition of carbohydrate or related molecular patterns by lectins and associated proteases |
| Alternative | C3 activation and amplification on surfaces that permit convertase persistence | C3bBb |
The classical and lectin pathways use different initiating complexes but share C4 and C2. All three converge on C3 activation and can feed into the common terminal pathway. Consequently, detection of downstream complement deposition alone does not necessarily identify the initiating route.
Clinical and laboratory significance
Inherited deficiencies of early classical-pathway components, including C1q, C1r, C1s, C2, and C4, can impair immune-complex and cellular-debris clearance. Such deficiencies are associated with susceptibility to infections and with autoimmune disease, particularly lupus or lupus-like disease. The associations differ among the components and do not mean that every affected individual develops the same condition.
Classical-pathway activation can also contribute to antibody-mediated tissue injury, including some forms of autoimmune hemolysis, immune-complex disease, and transplant injury. In these settings, complement may participate in disease rather than solely provide protection.
The CH50 assay assesses the functional integrity of the classical pathway and the shared terminal components, traditionally through lysis of antibody-sensitized erythrocytes. A reduced result can reflect component deficiency, complement consumption, or sample-handling problems; it does not by itself identify a particular defect. Measurements of individual components, such as C3 and C4, assess protein concentration rather than the function of the entire pathway.